#United States #New York #Class Action #Securities #PROCEPT BioRobotics

Overview of the Securities Class Action against PROCEPT BioRobotics Corporation

In the wake of significant stock price fluctuations, investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) are facing legal challenges due to a recent class action lawsuit filed on their behalf. The core of this lawsuit revolves around allegations of misleading information shared by the company regarding its handpiece sales and the overall demand for its AquaBeam Robotic Systems. With claims that the company presented an inflated view of sales and operational performance, this situation has left many shareholders questioning their investments.

Details of the Legal Filing

The class action complaint indicates that shareholders who purchased securities between February 28, 2024, and February 25, 2026, may be eligible to claim damages resulting from these alleged deceptions. PROCEPT's stock experienced a dramatic decline of over 75%—dropping from approximately $100 per share to below $25—prompting investigations into their disclosure practices. This lawsuit demands accountability from the company for what appears to be a pattern of inconsistent disclosures regarding handpiece utilization and sales.

Timeline of Disclosure Failures

The securities action outlines a timeline of events that contributed to this troubling situation:

• - February 2024: PROCEPT reported increased U.S. handpiece revenues, attributing this growth to rising utilization.
• - May 2024: Management reassured investors that handpiece orders were sustainable and aligned with procedures conducted.
• - April 2025: The CFO projected high expectations for handpiece sales, fostering confidence among investors.
• - August 2025: PROCEPT announced issues with handpiece shipments and a downward revision of guidance, citing significant leadership changes.
• - November 2025: The company reduced annual handpiece guidance further, raising concerns about operational effectiveness.
• - February 2026: Actual procedure data was revealed, showcasing a troubling contraction in handpiece units, coupled with excess inventory.

Each of these disclosures marks a significant contrast in narrative, hinting at a gap between real market demand and the company's reported figures. As further information unfolded, it became clearer that investors were not fully informed of the company's practices, including a discount program encouraging bulk orders.

Implications for Shareholders

The crux of the lawsuit lies in the perceived discrepancy between reported handpiece sales and real procedural utilization, leading to serious questions about the integrity of PROCEPT's financial reporting. Joseph E. Levi, the attorney representing the shareholders, emphasized that "timely disclosure of material events is crucial for maintaining fair and efficient markets. The rise and fall of shareholder confidence hinge on transparency, especially in times of volatile stock performance."

Eligibility for Claimants

Investors who bought PRCT stock during the specified period and have incurred losses are urged to seek information on their eligibility for this lawsuit. Those interested in participating must act promptly as the deadline to serve as a lead plaintiff is September 22, 2026. Key documents to gather include brokerage statements proving purchase dates and share quantities.

Conclusion

This lawsuit sheds light on the responsibilities of companies like PROCEPT BioRobotics in providing accurate and truthful information to their investors. As this case unfolds, it raises critical conversations about corporate governance and accountability. Shareholders are advised to stay informed and consider their options regarding this class action.

For further details and to determine eligibility, affected investors can contact Joseph E. Levi, Esq., at [email protected] or via phone at (888) SueWallSt.